#United States #Chicago #Colorectal Cancer #KLEOS #GCAR

Transforming Clinical Trials: The Launch of KLEOS

In a groundbreaking initiative, the Colorectal Cancer Alliance has partnered with the Global Coalition for Adaptive Research (GCAR) to introduce the KLEOS platform, a revolutionary adaptive clinical trial design aimed specifically at tackling colorectal cancer (CRC). CRC has tragically become the deadliest cancer among individuals under 50 and poses a significant risk globally, ranking as the second leading cause of cancer-related deaths. This collaboration intends to change that narrative.

The launch of KLEOS is backed by a substantial donation of $7.5 million aimed at catalyzing multi-phase studies that will expedite research into CRC. The unveiling of this innovative trial platform will take place during the American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 to June 2, 2026, in Chicago. This event marks a significant milestone, welcoming experts from the Project Cure CRC Consortium to strategize on the platform’s rollout and operationalization.

The KLEOS trial is designed as an adaptive trial platform, providing a singular, flexible structure to evaluate multiple treatment strategies simultaneously. This approach stands in stark contrast to traditional clinical trials, which often operate under rigid protocols that can hinder the speed of research and the introduction of new therapies. With KLEOS, researchers can rapidly test novel therapeutics and combinations that show the most promise, allowing for real-time data analysis and decision-making.

The ambitious goals of the KLEOS platform involve broadening access to cutting-edge treatment options for patients while simultaneously generating high-quality data to guide clinical practices. The name KLEOS, meaning “glory” in Greek, is a poignant reminder of the lives affected by CRC, honoring those lost and emphasizing the urgent need for breakthroughs in treatment.

Dr. Meredith Buxton, CEO of GCAR, highlights the vision behind KLEOS, “The future of clinical development hinges on innovative, integrated frameworks that allow us to respond effectively to the needs of patients.” This sentiment is echoed by John Marshall, M.D., Chief Medical Consultant for the Colorectal Cancer Alliance, who notes the critical need for improved survival rates among late-stage CRC patients, which currently stand at a disheartening 13% over five years. He emphasizes that KLEOS seeks to critically enhance therapeutic options for those diagnosed with CRC, noting that, “The urgency behind this innovative trial platform aims to accelerate cures.”

The proposed methodology of KLEOS is characterized by key features designed to optimize research efficiency. It allows for the seamless introduction of new treatment arms as novel therapies emerge. By utilizing interim analyses, researchers can make data-driven decisions in real-time, thereby adjusting strategies as necessary to ensure the most effective treatments are explored.

With the patient experience at its core, KLEOS nurtures a more personalized research approach, matching therapies with patients based on the latest findings. Drug developers will benefit through an efficient means to assess novel therapies, potentially getting effective options into the hands of patients more quickly than traditional methods would permit.

As the Colorectal Cancer Alliance and GCAR pave the way for this adaptive trial model, they invite pharmaceutical and biotechnology companies to engage with their innovative framework during the ASCO Annual Meeting. This collaborative effort represents a significant step towards developing a more responsive clinical research landscape that prioritizes patient needs and accelerates the overall pace of therapeutic advancements.

In summary, the introduction of the KLEOS adaptive clinical trial platform represents a beacon of hope for those grappling with colorectal cancer. By embracing innovation and collaboration, the Colorectal Cancer Alliance and GCAR aim to not only honor the legacy of those lost to this disease but also to fundamentally alter the landscape of CRC treatment for a brighter future.